All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Visual abstract| Pooled allogeneic faecal microbiota therapy for steroid resistant GI-aGvHD
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Severe gastrointestinal acute graft versus host disease (GI-aGvHD) is a serious complication that can occur after allogeneic hematopoietic cell transplantation (allo-HCT). Gut dysbiosis and a loss of bacterial diversity in the intestinal microbiome post-transplantation is thought to be an important factor in the development of the condition.
Fecal microbiota transplant is currently under investigation for the treatment of GI-aGvHD, with several pilot studies highlighting encouraging data. While the issue of donor sourcing remains a problem for fecal microbiota transplantation, one potential solution has been the development of a standardized fecal microbiota transplant product, MaaT013. This new form of microbiota therapy has previously been reported on the GvHD Hub.
Recently, Malard et al. performed the multicenter, single arm phase II HERACLES study (NCT03359980) investigating the safety and efficacy of MaaT013 in patients diagnosed with steroid-refractory GI-aGvHD. Here, we summarize the key results.
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox